ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Monday

ADC Therapeutics (NYSE:ADCT - Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.38) per share and revenue of $17.71 million for the quarter.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.06. The firm had revenue of $19.00 million for the quarter, compared to the consensus estimate of $19.01 million. On average, analysts expect ADC Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ADC Therapeutics Stock Performance

Shares of ADCT traded up $0.02 during mid-day trading on Friday, reaching $1.45. The stock had a trading volume of 326,850 shares, compared to its average volume of 615,132. The business has a fifty day moving average of $1.47 and a 200 day moving average of $1.92. The firm has a market cap of $143.31 million, a price-to-earnings ratio of -0.60 and a beta of 1.55. ADC Therapeutics has a 12 month low of $1.05 and a 12 month high of $5.17.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of ADC Therapeutics in a research note on Friday, March 7th. Stephens increased their target price on ADC Therapeutics from $6.00 to $8.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. Guggenheim dropped their price target on ADC Therapeutics from $10.00 to $7.00 and set a "buy" rating for the company in a research note on Monday, March 31st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective on shares of ADC Therapeutics in a report on Monday, March 31st. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, ADC Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $7.75.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.